Viral Infections in Dialysis Patients Part A: Human Immunodeficiency Virus Infection in Dialysis Patients
What is the preferential mode of renal replacement therapy for ESRD patients, if the long-term prognosis is determined by the nature and severity of viral infection?
What are the different therapeutic strategies to treat these infected patients, such as the deployment of antiviral drugs, immunomodulators, and others, and their adverse effects in patients with compromised renal function?
What are the combined effects of superimposition of immunosuppression on chronic uremia, maintenance dialysis, renal transplantation, and immunosuppressive therapy, on the natural history of viral disease, especially in patients infected with the human immunodeficiency virus (HIV) which preferentially affects the T cell system?
KeywordsPeritoneal Dialysis Continuous Ambulatory Peritoneal Dialysis Chronic Uremia
Unable to display preview. Download preview PDF.
- 1. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 36 (No 1S): 3S, 1987Google Scholar
- 2. 1993 revised classification system for HIV infection and expanded case definition for AIDS among adolescents and adults. MMWR 41 (No RR-17): 1, 1992Google Scholar
- 8.Rao TKS, Friedman EA: Outcome of severe acute renal failure in patients with the acquired immunodeficiency syndrome. In pressGoogle Scholar
- 9.Rao TKS, Berns JS: Acute renal failure in patients with HIV infection. in Renal and urologic aspects of HIV infection, edited by Kimmel PL, Berns JS, New York, Churchill Livingstone. In pressGoogle Scholar
- 13.Cohen AH, Sun NCJ, Shapshak P, Imagawa DT: Demonstration of human immunodeficiency virus in renal epithelium in HIV-associated nephropathy. Modern Pathol 2: 125, 1989Google Scholar
- 17.United States Renal Data System: 1993 annual data report, p 24Google Scholar
- 18.ESRD Network of New York: 1992 annual report. July 1993Google Scholar
- 19.Tokras JI, Alter MJ, Favero MS, Moyer LA, Bland LA: National Surveillance of dialysis-associated diseases in the United States, 1992. ASAIO J. In pressGoogle Scholar
- 20.Rao TKS: Acquired immunodeficiency syndrome human immunodeficiency virus and dialysis. in: International Yearbook of Nephrology 1991, edited by Andreucci VE, Fine LG, Boston, MA, Kluwer Academic publishers, 1990, p 199Google Scholar
- 23.Ribot S, Dean D, Goldblat M, Saavedra M: Prognosis of HIV positive dialysis patients. Kidney Int 37: 315, 1990Google Scholar
- 28.Campbell J, Markowitz N, Fisher EJ, Cruz C: Continuous ambulatory peritoneal dialysis for the AIDS patient. in Ambulatory Peritoneal dialysis, edited by Avram MM, Giordano C, New York, Plenum Publishing Co, 1990, p 266Google Scholar
- 30.Rubin J: Prevalence of HIV virus among patients undergoing continuous ambulatory peritoneal dialysis. Trans Am Soc Artif Intern Organs 35: 144, 1989Google Scholar
- 35.Wasser WG, Boyle MJ, Brandon S, Gruber SJ, Winston RV, Feldman NS: HIV positivity does not predispose peritoneal dialysis patients to peritonitis. J Am Soc Nephrol 2: 369, 1991Google Scholar
- 44.Shrivastava D, Rao TKS, Sinert R, Khurana E, Lundin AP, Friedman EA: The efficacy of erythropoietin in HIV infected end stage renal disease patients treated by maintenance hemodialysis. In pressGoogle Scholar
- 45.Berns JS, Cohen RM, Rudnick MR, Bennett WM: Renal aspects of antimicrobial therapy for HIV infection. in Renal and urologic aspects of HIV infection, edited by Kimmel PL, Berns JS, New York, Churchill Livingstone. In pressGoogle Scholar
- 46.Descamps-Latscha B, Herbelin A: Long-term dialysis and cellular immunity: a critical survey. Kidney Int 43(Suppl 41): S135, 1993Google Scholar
- 47.Chatenoud L, Herbelin A, Beaurain G, Descamps-Latscha B: Immune deficiency of the uremic patient. Adv Nephrol 19: 259, 1990Google Scholar
- 49.Pinching AJ: Antibody responses in HIV infection. Clin Exp Immunol 84: 181, 1989Google Scholar
- 54. Update: Universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodbome pathogens in health-care settings. MMWR 37: 377, 1988Google Scholar
- 55. Guidelines for for prevention of transmission of human immunodeficiency virus and hepatitis B virus to healthcare and public safety workers. MMWR 38 (S-6): 1, 1989Google Scholar
- 56. Recommendations for preventing transmission of human immunodeficiency virus and hepatitis B virus to patients during exposure-prone invasive procedures. MMWR 40 (RR-8): 1, 1991Google Scholar
- 57.Martin LS, McDougal SJ, Loskoski SL: Disinfection and inactivation of Human T Lymphotropic virus type III/Lymphadenopathy-associated virus. J Infect Dis 152: 39, 1985Google Scholar
- 58.Shapshak P, McCoy CB, Rivers JE et ai: Inactivation of human immunodeficiency virus-1 at short time intervals using undiluted bleach. J Acqd Immune Def Synd 6: 218, 1993Google Scholar
- 60.Perez GO, Ortiz C, De Medina M, Schiff E, Bourgoignie JJ: Lack of transmission of human immunodeficiency virus in chronic hemodialysis patients. Am J Nephrol 8: 123Google Scholar